BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25041458)

  • 1. Serological markers associated with disease behavior and response to anti-tumor necrosis factor therapy in ulcerative colitis.
    Kevans D; Waterman M; Milgrom R; Xu W; Van Assche G; Silverberg M
    J Gastroenterol Hepatol; 2015 Jan; 30(1):64-70. PubMed ID: 25041458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.
    Zholudev A; Zurakowski D; Young W; Leichtner A; Bousvaros A
    Am J Gastroenterol; 2004 Nov; 99(11):2235-41. PubMed ID: 15555007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to Escherichia coli outer membrane porin C in the absence of anti-Saccharomyces cerevisiae antibodies and anti-neutrophil cytoplasmic antibodies are an unreliable marker of Crohn disease and ulcerative colitis.
    Davis MK; Andres JM; Jolley CD; Novak DA; Haafiz AB; González-Peralta RP
    J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):409-13. PubMed ID: 18030205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis.
    Sura SP; Ahmed A; Cheifetz AS; Moss AC
    J Clin Gastroenterol; 2014 Apr; 48(4):351-5. PubMed ID: 24492405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy.
    Olbjørn C; Cvancarova Småstuen M; Thiis-Evensen E; Nakstad B; Vatn MH; Perminow G
    Scand J Gastroenterol; 2017 Apr; 52(4):414-419. PubMed ID: 27887202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.
    Papp M; Altorjay I; Dotan N; Palatka K; Foldi I; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Norman GL; Szamosi T; Papp J; ; Lakatos PL
    Am J Gastroenterol; 2008 Mar; 103(3):665-81. PubMed ID: 18047543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological markers predict inflammatory bowel disease years before the diagnosis.
    van Schaik FD; Oldenburg B; Hart AR; Siersema PD; Lindgren S; Grip O; Teucher B; Kaaks R; Bergmann MM; Boeing H; Carbonnel F; Jantchou P; Boutron-Ruault MC; Tjønneland A; Olsen A; Crowe FL; Peeters PH; van Oijen MG; Bueno-de-Mesquita HB
    Gut; 2013 May; 62(5):683-8. PubMed ID: 22842615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
    Peeters M; Joossens S; Vermeire S; Vlietinck R; Bossuyt X; Rutgeerts P
    Am J Gastroenterol; 2001 Mar; 96(3):730-4. PubMed ID: 11280542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pANCA and ASCA in Children with IBD-Unclassified, Crohn's Colitis, and Ulcerative Colitis-A Longitudinal Report from the IBD Porto Group of ESPGHAN.
    Birimberg-Schwartz L; Wilson DC; Kolho KL; Karolewska-Bochenek K; Afzal NA; Spray C; Romano C; Lionetti P; Hauer AC; Martinez-Vinson C; Veres G; Escher JC; Turner D;
    Inflamm Bowel Dis; 2016 Aug; 22(8):1908-14. PubMed ID: 27135480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical significance of antimicrobial serologic responses within an Irish Crohn's disease population.
    O'Donnell S; O'Sullivan M; O'Morain CA; Ryan BM
    Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1464-9. PubMed ID: 24047859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China.
    Zhou F; Xia B; Wang F; Shrestha UK; Chen M; Wang H; Shi X; Chen Z; Li J
    Clin Chim Acta; 2010 Oct; 411(19-20):1461-5. PubMed ID: 20570669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
    Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
    Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease.
    Mahler M; Bogdanos DP; Pavlidis P; Fritzler MJ; Csernok E; Damoiseaux J; Bentow C; Shums Z; Forbes A; Norman GL
    Clin Chim Acta; 2013 Sep; 424():267-73. PubMed ID: 23806819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of serum antibodies in patients suspected of having inflammatory bowel disease.
    Jaskowski TD; Litwin CM; Hill HR
    Clin Vaccine Immunol; 2006 Jun; 13(6):655-60. PubMed ID: 16760323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study.
    Nørgård BM; Nielsen J; Qvist N; Gradel KO; de Muckadell OB; Kjeldsen J
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1301-9. PubMed ID: 22506582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.
    Yacyshyn BR; Schievella A; Sewell KL; Tami JA
    Clin Exp Immunol; 2005 Jul; 141(1):141-7. PubMed ID: 15958080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnostic role of anti-saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease].
    Gao X; Hu PJ; He Y; Liao SY; Peng S; Chen MH
    Zhonghua Nei Ke Za Zhi; 2005 Jun; 44(6):428-30. PubMed ID: 16008854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease.
    de Vries M; van der Horst-Bruinsma I; van Hoogstraten I; van Bodegraven A; von Blomberg BM; Ratnawati H; Dijkmans B
    J Rheumatol; 2010 Nov; 37(11):2340-4. PubMed ID: 20810508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relevance of serologic studies in inflammatory bowel diseases].
    Papp M; Altorjay I; Lakatos PL
    Orv Hetil; 2007 May; 148(19):887-96. PubMed ID: 17478404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease.
    Esters N; Vermeire S; Joossens S; Noman M; Louis E; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; Poulain D; Bossuyt X; Rutgeerts P;
    Am J Gastroenterol; 2002 Jun; 97(6):1458-62. PubMed ID: 12094865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.